Subcutaneous CD19-Binding T Cell Engagers for Outpatient Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapies like blinatumomab require lengthy hospitalization and are prone to infusion-related side effects, necessitating a more convenient and safe administration method that minimizes adverse events and reduces hospitalization time.
Innovation Solution
Subcutaneous administration of T cell engagers, such as blinatumomab, with optimized dosing regimens that include predetermined periods and treatment-free intervals to manage side effects and improve pharmacokinetic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous infusion of T cell engagers is used, then therapeutic efficacy is achieved, but infusion-related side effects and hospitalization time increase
Solution Approach 1:
The patent changes the administration route parameter from intravenous to subcutaneous, and modifies dosing parameters (fixed subcutaneous doses of 30μg, 60μg, or 90μg). This parameter change eliminates infusion-related reactions while maintaining therapeutic efficacy through optimized subcutaneous absorption kinetics
Solution Approach 2:
The patent extracts the T cell engager from the intravenous administration system and delivers it through subcutaneous injection, thereby separating the therapeutic agent from the problematic infusion mechanism and its associated side effects
2Reliability
If continuous intravenous administration is used, then therapeutic effect is maintained, but treatment duration and hospitalization time increase
Solution Approach 1:
The patent implements periodic dosing schedules (once weekly, twice weekly, or three times weekly) with treatment-free intervals between cycles. This periodic administration maintains therapeutic effect while enabling outpatient treatment and reducing continuous hospitalization time
Solution Approach 2:
The patent introduces flexible dosing dynamics with multiple dose levels (30μg, 60μg, 90μg) and adjustable frequency options, allowing treatment to be adapted to patient response and enabling discharge from continuous hospitalization
3Ease of operation
If subcutaneous administration is used, then patient convenience and cost are improved, but dosing regimen optimization is required to maintain efficacy
Solution Approach 1:
The patent establishes specific subcutaneous dosing parameters (30μg, 60μg, or 90μg fixed doses) with defined administration frequencies. These optimized parameters balance patient convenience with maintained therapeutic efficacy, eliminating the need for complex individualized dosing adjustments
Data Source
AI summary
The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3 chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.